Prostate cancer imaging with a new monoclonal antibody: A preliminary report
Identifieur interne : 000162 ( Main/Exploration ); précédent : 000161; suivant : 000163Prostate cancer imaging with a new monoclonal antibody: A preliminary report
Auteurs : RBID : ISTEX:10434_1994_Article_BF02303812.pdfEnglish descriptors
Abstract
Background: Optimal treatment of prostate cancer depends on accurate staging. Computed tomography (CT) and magnetic resonance imaging have severe limitations, and standard bone scanning can show only destructive osseous metastases. A radiolabeled antibody specific to prostatic adenocarcinoma could theoretically find evidence of soft-tissue metastases and lymph node involvement.Methods: An immunoconjugate (CYT-356) consisting of a murine monoclonal antibody against human prostatic adenocarcinoma bound to a linkerchelator and radiolabeled with indium 111 was administered intravenously to seven patients with documented Stage D adenocarcinoma of the prostate. Planar imaging was done on days 1, 2, and 3 after injection. The CYT-356 scans were compared with standard technetium Tc 99m sulfur colloid bone scans and CT scans.Results: Optimal imaging results were obtained on the 72-h scans. All patients had lesions on both the99mTc-sulfur colloid bone scan and the CYT-356 scan. The location of the lesions correlated to a great extent. Two patients had positive lesions biopsied, and both biopsies showed the presence of metastatic prostatic carcinoma. There were no side effects from administration of the antibody.Conclusion: In this preliminary study, CYT-356 scanning appears to be a promising agent to accomplish specific staging of prostatic carcinoma.
DOI: 10.1007/BF02303812
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Prostate cancer imaging with a new monoclonal antibody: A preliminary report</title><author><name>Edgar Sanford</name><affiliation wicri:level="1"><mods:affiliation>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine</wicri:regionArea><wicri:noRegion>University of South Florida College of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><mods:affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>the James A. Haley Veterans Administration Hospital, Tampa, Florida</wicri:regionArea><wicri:noRegion>Florida</wicri:noRegion></affiliation></author><author><name>Robert Grzonka</name><affiliation wicri:level="1"><mods:affiliation>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine</wicri:regionArea><wicri:noRegion>University of South Florida College of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><mods:affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>the James A. Haley Veterans Administration Hospital, Tampa, Florida</wicri:regionArea><wicri:noRegion>Florida</wicri:noRegion></affiliation></author><author><name>Albert Heal</name><affiliation wicri:level="1"><mods:affiliation>the Department of Radiology, Division of Nuclear Medicine, University of South Florida College of Medicine, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>the Department of Radiology, Division of Nuclear Medicine, University of South Florida College of Medicine</wicri:regionArea><wicri:noRegion>University of South Florida College of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><mods:affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>the James A. Haley Veterans Administration Hospital, Tampa, Florida</wicri:regionArea><wicri:noRegion>Florida</wicri:noRegion></affiliation></author><author><name>Mohammad Helal</name><affiliation wicri:level="1"><mods:affiliation>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine</wicri:regionArea><wicri:noRegion>University of South Florida College of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><mods:affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>the James A. Haley Veterans Administration Hospital, Tampa, Florida</wicri:regionArea><wicri:noRegion>Florida</wicri:noRegion></affiliation></author><author><name>Lester Persky</name><affiliation wicri:level="1"><mods:affiliation>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine</wicri:regionArea><wicri:noRegion>University of South Florida College of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><mods:affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>the James A. Haley Veterans Administration Hospital, Tampa, Florida</wicri:regionArea><wicri:noRegion>Florida</wicri:noRegion></affiliation></author><author><name>Ian Tyson</name><affiliation wicri:level="1"><mods:affiliation>the Department of Radiology, Division of Nuclear Medicine, University of South Florida College of Medicine, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>the Department of Radiology, Division of Nuclear Medicine, University of South Florida College of Medicine</wicri:regionArea><wicri:noRegion>University of South Florida College of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><mods:affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>the James A. Haley Veterans Administration Hospital, Tampa, Florida</wicri:regionArea><wicri:noRegion>Florida</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:10434_1994_Article_BF02303812.pdf</idno><date when="1994">1994</date><idno type="doi">10.1007/BF02303812</idno><idno type="wicri:Area/Main/Corpus">000C83</idno><idno type="wicri:Area/Main/Curation">000C83</idno><idno type="wicri:Area/Main/Exploration">000162</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Murine monoclonal antibody</term><term>Prostate cancer</term><term>Radiolabeled antibody</term><term>Staging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Background: Optimal treatment of prostate cancer depends on accurate staging. Computed tomography (CT) and magnetic resonance imaging have severe limitations, and standard bone scanning can show only destructive osseous metastases. A radiolabeled antibody specific to prostatic adenocarcinoma could theoretically find evidence of soft-tissue metastases and lymph node involvement.Methods: An immunoconjugate (CYT-356) consisting of a murine monoclonal antibody against human prostatic adenocarcinoma bound to a linkerchelator and radiolabeled with indium 111 was administered intravenously to seven patients with documented Stage D adenocarcinoma of the prostate. Planar imaging was done on days 1, 2, and 3 after injection. The CYT-356 scans were compared with standard technetium Tc 99m sulfur colloid bone scans and CT scans.Results: Optimal imaging results were obtained on the 72-h scans. All patients had lesions on both the99mTc-sulfur colloid bone scan and the CYT-356 scan. The location of the lesions correlated to a great extent. Two patients had positive lesions biopsied, and both biopsies showed the presence of metastatic prostatic carcinoma. There were no side effects from administration of the antibody.Conclusion: In this preliminary study, CYT-356 scanning appears to be a promising agent to accomplish specific staging of prostatic carcinoma.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="df4223c7c3e490397ab797f21fb4a660a83828ed"><titleInfo lang="eng"><title>Prostate cancer imaging with a new monoclonal antibody: A preliminary report</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="given">Edgar</namePart><namePart type="family">Sanford</namePart><namePart type="termsOfAddress">MD</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine, USA</affiliation><affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</affiliation></name><name type="personal"><namePart type="termsOfAddress"></namePart><namePart type="given">Robert</namePart><namePart type="family">Grzonka</namePart><namePart type="termsOfAddress">MD</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine, USA</affiliation><affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</affiliation></name><name type="personal"><namePart type="termsOfAddress"></namePart><namePart type="given">Albert</namePart><namePart type="family">Heal</namePart><namePart type="termsOfAddress">PhD</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>the Department of Radiology, Division of Nuclear Medicine, University of South Florida College of Medicine, USA</affiliation><affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</affiliation></name><name type="personal"><namePart type="termsOfAddress"></namePart><namePart type="given">Mohammad</namePart><namePart type="family">Helal</namePart><namePart type="termsOfAddress">MD</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine, USA</affiliation><affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</affiliation></name><name type="personal"><namePart type="termsOfAddress"></namePart><namePart type="given">Lester</namePart><namePart type="family">Persky</namePart><namePart type="termsOfAddress">MD</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>From the Department of Surgery, Division of Urology, University of South Florida College of Medicine, USA</affiliation><affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</affiliation></name><name type="personal"><namePart type="termsOfAddress"></namePart><namePart type="given">Ian</namePart><namePart type="family">Tyson</namePart><namePart type="termsOfAddress">MD</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>the Department of Radiology, Division of Nuclear Medicine, University of South Florida College of Medicine, USA</affiliation><affiliation>the James A. Haley Veterans Administration Hospital, Tampa, Florida, USA</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, New York</publisher><dateCreated encoding="w3cdtf">1993-06-01</dateCreated><dateCaptured encoding="w3cdtf">1993-10-13</dateCaptured><dateValid encoding="w3cdtf">2006-01-07</dateValid><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Background: Optimal treatment of prostate cancer depends on accurate staging. Computed tomography (CT) and magnetic resonance imaging have severe limitations, and standard bone scanning can show only destructive osseous metastases. A radiolabeled antibody specific to prostatic adenocarcinoma could theoretically find evidence of soft-tissue metastases and lymph node involvement.Methods: An immunoconjugate (CYT-356) consisting of a murine monoclonal antibody against human prostatic adenocarcinoma bound to a linkerchelator and radiolabeled with indium 111 was administered intravenously to seven patients with documented Stage D adenocarcinoma of the prostate. Planar imaging was done on days 1, 2, and 3 after injection. The CYT-356 scans were compared with standard technetium Tc 99m sulfur colloid bone scans and CT scans.Results: Optimal imaging results were obtained on the 72-h scans. All patients had lesions on both the99mTc-sulfur colloid bone scan and the CYT-356 scan. The location of the lesions correlated to a great extent. Two patients had positive lesions biopsied, and both biopsies showed the presence of metastatic prostatic carcinoma. There were no side effects from administration of the antibody.Conclusion: In this preliminary study, CYT-356 scanning appears to be a promising agent to accomplish specific staging of prostatic carcinoma.</abstract><subject lang="eng"><genre>Key Words</genre><topic>Prostate cancer</topic><topic>Staging</topic><topic>Radiolabeled antibody</topic><topic>Murine monoclonal antibody</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Annals of Surgical Oncology</title></titleInfo><titleInfo><title>Annals of Surgical Oncology</title><partNumber>Year: 1994</partNumber><partNumber>Volume: 1</partNumber><partNumber>Number: 5</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1994-09-01</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Surgery</topic><topic>Oncology</topic><topic>Surgical Oncology</topic></subject><identifier type="issn">1068-9265</identifier><identifier type="issn">Electronic: 1534-4681</identifier><identifier type="matrixNumber">10434</identifier><identifier type="local">IssueArticleCount: 14</identifier><recordInfo><recordOrigin>The Society of Surgical Oncology, Inc., 1994</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF02303812</identifier><identifier type="matrixNumber">Art8</identifier><identifier type="local">BF02303812</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>400</start><end>404</end></extent></part><recordInfo><recordOrigin>The Society of Surgical Oncology, Inc., 1994</recordOrigin><recordIdentifier>10434_1994_Article_BF02303812.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000162 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000162 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:10434_1994_Article_BF02303812.pdf
|texte= Prostate cancer imaging with a new monoclonal antibody: A preliminary report
}}
| This area was generated with Dilib version V0.5.81. |  |